- Home
- NXTC vs HTCR Comparison
NXTC vs HTCR Comparison
Compare NXTC & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- HTCR
- Stock Information
- Founded
- NXTC 2015
- HTCR 2009
- Country
- NXTC United States
- HTCR Japan
- Employees
- NXTC N/A
- HTCR N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- HTCR EDP Services
- Sector
- NXTC Health Care
- HTCR Technology
- Exchange
- NXTC Nasdaq
- HTCR Nasdaq
- Market Cap
- NXTC 12.8M
- HTCR 11.6M
- IPO Year
- NXTC 2019
- HTCR 2022
- Fundamental
- Price
- NXTC $5.12
- HTCR $0.51
- Analyst Decision
- NXTC Strong Buy
- HTCR
- Analyst Count
- NXTC 2
- HTCR 0
- Target Price
- NXTC $25.50
- HTCR N/A
- AVG Volume (30 Days)
- NXTC 318.4K
- HTCR 96.8K
- Earning Date
- NXTC 08-07-2025
- HTCR 08-13-2025
- Dividend Yield
- NXTC N/A
- HTCR 3.90%
- EPS Growth
- NXTC N/A
- HTCR N/A
- EPS
- NXTC N/A
- HTCR N/A
- Revenue
- NXTC N/A
- HTCR $29,625,381.00
- Revenue This Year
- NXTC N/A
- HTCR N/A
- Revenue Next Year
- NXTC N/A
- HTCR $8.59
- P/E Ratio
- NXTC N/A
- HTCR N/A
- Revenue Growth
- NXTC N/A
- HTCR 72.95
- 52 Week Low
- NXTC $2.69
- HTCR $0.39
- 52 Week High
- NXTC $19.80
- HTCR $3.38
- Technical
- Relative Strength Index (RSI)
- NXTC 48.99
- HTCR 56.25
- Support Level
- NXTC $4.75
- HTCR $0.45
- Resistance Level
- NXTC $5.23
- HTCR $0.50
- Average True Range (ATR)
- NXTC 0.31
- HTCR 0.04
- MACD
- NXTC 0.02
- HTCR 0.00
- Stochastic Oscillator
- NXTC 53.28
- HTCR 52.14
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About HTCR Heartcore Enterprises Inc.
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.